Chen Wei, Yoshida Shigeki, Ohara Noriyuki, Matsuo Hiroya, Morizane Mayumi, Maruo Takeshi
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Chuo-Ku, Kobe 650-0017, Japan.
J Clin Endocrinol Metab. 2005 Feb;90(2):884-92. doi: 10.1210/jc.2004-1591. Epub 2004 Nov 9.
The objective of this study was to elucidate the effects of GnRH antagonist Cetrorelix on proliferation and apoptosis in human leiomyoma cells cultured in vitro. Isolated leiomyoma cells were subcultured in phenol red-free DMEM supplemented with 10% fetal bovine serum for 120 h and then stepped down to serum-free conditions in the presence or absence of graded concentrations of Cetrorelix (10(-5) to 10(-8) mol/liter) for 6 d. Cultured leiomyoma cells were used for semiquantitative RT-PCR, immunocytochemistry, Western blot analysis, and terminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphosphate nick-end labeling assay. RT-PCR analysis revealed the presence of mRNAs encoding for GnRH receptor and epidermal growth factor (EGF) in cultured leiomyoma cells. The number of viable cultured leiomyoma cells was significantly (P < 0.01) decreased by treatment with Cetrorelix compared with untreated control cultures. Immunocytochemical examination demonstrated that treatment with Cetrorelix attenuated the expression of proliferating cell nuclear antigen (PCNA) and EGF in cultured leiomyoma cells. Western blot analysis revealed that treatment with 10(-5) mol/liter Cetrorelix significantly (P < 0.01) decreased PCNA expression. In addition, treatment with 10(-5) mol/liter Cetrorelix remarkably increased the terminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphosphate nick-end labeling-positive rate and poly(ADP-ribose) polymerase expression at 24 h of treatment compared with untreated control cultures (P < 0.01). Furthermore, treatment with 10(-5) mol/liter Cetrorelix decreased immunoreactive EGF protein and EGF mRNA expression in cultured leiomyoma cells at 4 d of treatment. GnRH antagonist Cetrorelix may directly inhibit leiomyoma cell growth by down-regulating proliferation in association with a decrease in EGF mRNA expression and by up-regulating apoptosis in those cells.
本研究的目的是阐明促性腺激素释放激素(GnRH)拮抗剂西曲瑞克对体外培养的人平滑肌瘤细胞增殖和凋亡的影响。将分离出的平滑肌瘤细胞在补充有10%胎牛血清的无酚红DMEM中传代培养120小时,然后在有或无梯度浓度西曲瑞克(10⁻⁵至10⁻⁸摩尔/升)的情况下转入无血清条件培养6天。培养的平滑肌瘤细胞用于半定量逆转录聚合酶链反应(RT-PCR)、免疫细胞化学、蛋白质印迹分析和末端脱氧核苷酸转移酶介导的脱氧尿苷5-三磷酸缺口末端标记法检测。RT-PCR分析显示培养的平滑肌瘤细胞中存在编码GnRH受体和表皮生长因子(EGF)的信使核糖核酸(mRNA)。与未处理的对照培养物相比,用西曲瑞克处理后,培养的存活平滑肌瘤细胞数量显著减少(P<0.01)。免疫细胞化学检查表明,用西曲瑞克处理可减弱培养的平滑肌瘤细胞中增殖细胞核抗原(PCNA)和EGF的表达。蛋白质印迹分析显示,用10⁻⁵摩尔/升西曲瑞克处理可使PCNA表达显著降低(P<0.01)。此外,与未处理的对照培养物相比,用10⁻⁵摩尔/升西曲瑞克处理在处理24小时时显著增加了末端脱氧核苷酸转移酶介导的脱氧尿苷5-三磷酸缺口末端标记阳性率和聚(ADP-核糖)聚合酶表达(P<0.01)。此外,用10⁻⁵摩尔/升西曲瑞克处理在处理4天时可降低培养的平滑肌瘤细胞中免疫反应性EGF蛋白和EGF mRNA表达。GnRH拮抗剂西曲瑞克可能通过下调增殖并伴随EGF mRNA表达降低以及上调这些细胞的凋亡来直接抑制平滑肌瘤细胞生长。